Table 1.
Baseline demographic and clinical characteristics of patients.
| Characteristics | All Patients (n = 5120) |
Class 1 (n = 3358) |
Class 2 (n = 782) |
Class 3 (n = 759) |
Fusion (n = 221) |
|---|---|---|---|---|---|
| Age | |||||
| Median—yr | 62 (20–90) | 62 (20–90) | 65 (20–90) | 64 (22–90) | 59 (20–90) |
| Distribution—No./total No. (%) | |||||
| <60 yr | 2180 (43) | 1532 (70) | 241 (11) | 291 (13) | 116 (5) |
| ≥60 yr | 2940 (57) | 1826 (62) | 541 (18) | 468 (16) | 105 (4) |
| Gender—No./total No. (%) | |||||
| Male | 2537 (50) | 1581 (62) | 400 (16) | 441 (17) | 115 (5) |
| Female | 2583 (50) | 1777 (69) | 382 (15) | 318 (12) | 106 (4) |
| Race—No./total No. (%) | |||||
| Asian | 212 (4) | 138 (65) | 24 (11) | 32 (15) | 18 (9) |
| Black | 192 (4) | 95 (50) | 42 (22) | 41 (21) | 14 (7) |
| White | 4504 (88) | 2977 (66) | 691 (15) | 659 (15) | 177 (4) |
| Other | 212 (4) | 148 (70) | 25 (12) | 27 (13) | 12 (6) |
| Sample type—No./total No. (%) | |||||
| Primary site | 2421 (47) | 1560 (64) | 387 (16) | 369 (15) | 105 (4) |
| Metastatic | 2122 (41) | 1379 (65) | 332 (16) | 304 (14) | 107 (5) |
| Not reported | 577 (11) | 419 (73) | 63 (11) | 86 (15) | 9 (2) |
| Type of Tumour—No./total No. (%) | |||||
| Melanoma | 1591 (31) | 1187 (35) | 189 (24) | 174 (23) | 41 (19) |
| Colorectal cancer | 1061 (21) | 842 (25) | 67 (9) | 136 (18) | 16 (7) |
| Non-small cell lung cancer | 714 (14) | 237 (7) | 243 (31) | 203 (27) | 31 (14) |
| Thyroid cancer | 689 (12) | 656 (20) | 14 (2) | 0 | 19 (9) |
| Glioma | 201 (4) | 118 (4) | 26 (3) | 23 (3) | 34 (15) |
| Unknown primary | 125 (2) | 56 (2) | 25 (3) | 38 (5) | 6 (3) |
| Bladder cancer | 39 (1) | 3 (0.1) | 16 (2) | 18 (2) | 2 (1) |
| Hepatobiliary | 75 (1) | 27 (0.8) | 20 (3) | 23 (3) | 5 (2) |
| Pancreatic cancer | 72 (1) | 25 (0.7) | 31 (4) | 5 (1) | 11 (5) |
| Prostate cancer | 72 (1) | 1 (0.03) | 42 (5) | 6 (1) | 22 (10) |
| Other | 481 (9) | 206 (6) | 108 (14) | 133 (18) | 34 (15) |
| Co-Mutations—No./total No. (%) | |||||
| NF-1 | 234 (5) | 59 (25) | 57 (24) | 114 (49) | 4 (2) |
| RAS (HRAS, NRAS, and/or KRAS) | 390 (8) | 44 (11) | 115 (30) | 225 (58) | 6 (2) |
| Variant Allele Frequency (%) | |||||
| <26% | 2242 (47) | 1446 (64) | 382 (17) | 414 (18) | - |
| ≥26% | 2485 (53) | 1802 (73) | 364 (15) | 319 (13) | - |